ScholarLens Back to search
2007•Journal of psychiatryRequires access

The second phase clinical trials of bupropion SR for the treatment of the major depressive disorder

Xiufeng Xu

Open publisher page 0 citations

Abstract

Objective The study was to determine the efficacy and safety of bupropion SR for treating depressive patients.Methods A control study was carried out between 58 patients . The 29 of total patients were treated with bupropion SR(300mg/d)and the others were treated with fluoxetine (20mg/d)for 6 weeks. The efficacy were assessed by Hamilton Depression Rating Scale(HAMD),Hamilton Anxiety Scale(HAMA), Clinical Global Impression (CGI) and the safety was assessed by Adverse Event scale.Results After six weeks treatment, the improvement rates of bupropion SR group and fluoxetine group were 86.2% and 69.0%, respectively (P0.05).The main adverse events of two groups were nausea,dry mouth, dizziness, diaphoresis and anorexia.There were no significant differences in improvement rate and incidence of adverse events between bupropion SR group and fluoxetine group.Conclusion Bupropion SR is an effective and safe antidepressant.

About this research paper

What this paper is about

Objective The study was to determine the efficacy and safety of bupropion SR for treating depressive patients.Methods A control study was carried out between 58 patients . The 29 of total patients were treated with bupropion SR(300mg/d)and the others were treated with fluoxetine (20mg/d)for 6 weeks. The efficacy were assessed by Hamilton Depression Rating Scale(HAMD),Hamilton Anxiety Scale(HAMA), Clinical Global Impression (CGI) and the safety was assessed by Adverse Event scale.Results After six weeks treatment, the improvement rates of bupropion SR group and fluoxetine group were 86.2% and 69.0%, respectively (P0.05).The main adverse events of two groups were nausea,dry mouth, dizziness, diaphoresis and anorexia.There were no significant differences in improvement rate and incidence of adverse events between bupropion SR group and fluoxetine group.Conclusion Bupropion SR is an effective and safe antidepressant.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective The study was to determine the efficacy and safety of bupropion SR for treating depressive patients.Methods A control study was carried out between 58 patients . The 29 of total patients were treated with bupropion SR(300mg/d)and the others were treated with fluoxetine (20mg/d)for 6 weeks. The efficacy were assessed by Hamilton Depression Rating Scale(HAMD),Hamilton Anxiety Scale(HAMA), Clinical Global Impression (CGI) and the safety was assessed by Adverse Event scale.Results After six weeks treatment, the improvement rates of bupropion SR group and fluoxetine group were 86.2% and 69.0%, respectively (P0.05).The main adverse events of two groups were nausea,dry mouth, dizziness, diaphoresis and anorexia.There were no significant differences in improvement rate and incidence of adverse events between bupropion SR group and fluoxetine group.Conclusion Bupropion SR is an effective and safe antidepressant.

Key concepts: Bupropion, Hamd, Nausea, Clinical Global Impression, Adverse effect, Hamilton Anxiety Rating Scale, Antidepressant, Fluoxetine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The second phase clinical trials of bupropion SR for the treatment of the major depressive disorder — Research Paper | ScholarLens